Amneal Pharmaceuticals Inc (NASDAQ: AMRX) kicked off on Tuesday, remained unchanged from the previous trading day, before settling in for the closing price of $8.62. Over the past 52 weeks, AMRX has traded in a range of $5.18-$9.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 11.64%. While this was happening, its average annual earnings per share was recorded 17.76%. With a float of $130.87 million, this company’s outstanding shares have now reached $309.88 million.
Let’s determine the extent of company efficiency that accounts for 8300 employees. In terms of profitability, gross margin is 36.52%, operating margin of 8.92%, and the pretax margin is -1.97%.
Amneal Pharmaceuticals Inc (AMRX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Amneal Pharmaceuticals Inc is 57.78%, while institutional ownership is 37.03%. The most recent insider transaction that took place on Mar 14 ’25, was worth 41,750,000. In this transaction 10% Owner of this company sold 5,000,000 shares at a rate of $8.35, taking the stock ownership to the 48,578,209 shares. Before that another transaction happened on Mar 14 ’25, when Company’s 10% Owner proposed sale 5,000,000 for $8.75, making the entire transaction worth $43,750,000.
Amneal Pharmaceuticals Inc (AMRX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 17.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.56% during the next five years compared to 32.70% growth over the previous five years of trading.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Trading Performance Indicators
Take a look at Amneal Pharmaceuticals Inc’s (AMRX) current performance indicators. Last quarter, stock had a quick ratio of 0.86. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.96. Likewise, its price to free cash flow for the trailing twelve months is 11.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit 0.17 in the next quarter and is forecasted to reach 0.82 in one year’s time.
Technical Analysis of Amneal Pharmaceuticals Inc (AMRX)
Looking closely at Amneal Pharmaceuticals Inc (NASDAQ: AMRX), its last 5-days average volume was 2.36 million, which is a jump from its year-to-date volume of 1.52 million. As of the previous 9 days, the stock’s Stochastic %D was 28.25%. Additionally, its Average True Range was 0.35.
During the past 100 days, Amneal Pharmaceuticals Inc’s (AMRX) raw stochastic average was set at 56.27%, which indicates a significant decrease from 65.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.13% in the past 14 days, which was lower than the 31.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.32, while its 200-day Moving Average is $8.01. However, in the short run, Amneal Pharmaceuticals Inc’s stock first resistance to watch stands at $8.80. Second resistance stands at $8.99. The third major resistance level sits at $9.23. If the price goes on to break the first support level at $8.38, it is likely to go to the next support level at $8.14. Now, if the price goes above the second support level, the third support stands at $7.95.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Key Stats
The company with the Market Capitalisation of 2.67 billion has total of 309,966K Shares Outstanding. Its annual sales at the moment are 2,794 M in contrast with the sum of -116,890 K annual income. Company’s last quarter sales were recorded 730,520 K and last quarter income was -31,080 K.
